To assess time to progression in patients with unresectable HCC receiving intra-arterial chemotherapy with cisplatin and mitomycin-C wk 7 of each cycle [clinicaltrials_resource:2f696e908d15932401d049fc0e52ebfc]

To assess time to progression in patients with unresectable HCC receiving intra-arterial chemotherapy with cisplatin and mitomycin-C wk 7 of each cycle [clinicaltrials_resource:2f696e908d15932401d049fc0e52ebfc]

CDDP 60mg/m2 + Mitomycin-C 12mg/m2
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:2f696e908d15932401d049fc0e52ebfc
A Phase II Study of Intra-arterial Chemotherapy With Cisplatin and Mitomycin-C in Patients With Hepatocellular Carcinoma [clinicaltrials:NCT00183885]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

To assess time to progression in patients with unresectable HCC receiving intra-arterial chemotherapy with cisplatin and mitomycin-C wk 7 of each cycle [clinicaltrials_resource:2f696e908d15932401d049fc0e52ebfc]

CDDP 60mg/m2 + Mitomycin-C 12mg/m2
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:2f696e908d15932401d049fc0e52ebfc
Bio2RDF identifier
2f696e908d15932401d049fc0e52ebfc
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:2f696e908d15932401d049fc0e52ebfc
measure [clinicaltrials_vocabulary:measure]
To assess time to progression ...... with cisplatin and mitomycin-C
time frame [clinicaltrials_vocabulary:time-frame]
description
CDDP 60mg/m2 + Mitomycin-C 12mg/m2
identifier
clinicaltrials_resource:2f696e908d15932401d049fc0e52ebfc
title
To assess time to progression ...... mitomycin-C wk 7 of each cycle
@en
inDataset
type
label
To assess time to progression ...... 96e908d15932401d049fc0e52ebfc]
@en